Novartis Says Acromegaly Drug Met Primary Goal in Late-Stage Study

Novartis said results from a late-stage study showed its novel therapy pasireotide long-acting release to be more effective than the current standard medical therapy in patients with acromegaly — a rare hormonal disorder. The study met its primary endpoint.
RTT News